

Not for distribution, directly or indirectly, in the United States of America, Canada, Australia and Japan.

MAUNA KEA TECHNOLOGIES WELCOMES NEW FRENCH AND INTERNATIONAL SHAREHOLDERS

PARIS, FRANCE – May 15, 2014 – Mauna Kea Technologies (Euronext: MKEA, FR0010609263, PEA-PME eligible), leader in the optical biopsy market, has just been informed that CREADEV, one of its historical shareholders previously holding a stake of close to 17% in the Company, has sold its shares to French, European and American investors and is now holding less than 3% of the capital.

In accordance with ongoing regulations, CREADEV and investors having participated in the placement are required to declare when they cross certain shareholding thresholds.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops, and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic duct, lungs, and during fine needle aspiration procedures. Cellvizio has also been cleared by SFDA in China and MHLW in Japan for use in the GI, respiratory and urinary tract.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Westwicke Partners

Investor Relations US
Mark Klausner
Tel: 443 213 0501
mark.klausner@westwicke.com

NewCap.

Investor Relations Europe
Florent Alba
Tel: +33 (0) 1 44 71 94 94
maunakea@newcap.fr

DISCLAIMER

This document does not constitute, and shall not be considered as constituting, an offer to sell or a solicitation of an offer to buy securities in any jurisdiction.